Challenging the standard of care in advanced melanoma: focus on pembrolizumab
Raghad M Abdul-Karim,1 C Lance Cowey2–4 1Baylor Sammons Cancer Center, 2Melanoma and Genitourinary Oncology Program, Baylor University Medical Center, Sammons Cancer Center Texas Oncology,3Baylor Skin Malignancy Research and Treatment Center, Baylor University Medical Center, 4Developmenta...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-09-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/challenging-the-standard-of-care-in-advanced-melanoma-focus-on-pembrol-peer-reviewed-article-CMAR |
id |
doaj-f8432748406a42f6ab1f70560ee08b71 |
---|---|
record_format |
Article |
spelling |
doaj-f8432748406a42f6ab1f70560ee08b712020-11-24T23:45:11ZengDove Medical PressCancer Management and Research1179-13222017-09-01Volume 943344234854Challenging the standard of care in advanced melanoma: focus on pembrolizumabAbdul-Karim RMCowey CLRaghad M Abdul-Karim,1 C Lance Cowey2–4 1Baylor Sammons Cancer Center, 2Melanoma and Genitourinary Oncology Program, Baylor University Medical Center, Sammons Cancer Center Texas Oncology,3Baylor Skin Malignancy Research and Treatment Center, Baylor University Medical Center, 4Developmental Therapeutics Program, US Oncology Research, Dallas, TX, USA Abstract: The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability to improve both response rates and survival outcomes. Pembrolizumab, an immune checkpoint inhibitor that blocks the negative regulatory PD-1 receptor on T-cell lymphocytes, has shown improved efficacy compared to standard therapies with an acceptable tolerability profile. Additionally, this agent is being evaluated in adjuvant and combination trial strategies that have great potential to further advance outcomes. This review focuses on the advances that pembrolizumab has made in melanoma and what studies are upcoming that could change the future of melanoma treatment yet again. Keywords: keytruda, MK-3475, immune checkpoint inhibitor, PD-1 inhibitor, adjuvant therapy, combination therapies, immunotherapyhttps://www.dovepress.com/challenging-the-standard-of-care-in-advanced-melanoma-focus-on-pembrol-peer-reviewed-article-CMARPembrolizumabKeytrudaMK-3475MelanomaImmune Checkpoint InhibitorPD-1 InhibitorAdjuvant TherapyCombination Therapies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdul-Karim RM Cowey CL |
spellingShingle |
Abdul-Karim RM Cowey CL Challenging the standard of care in advanced melanoma: focus on pembrolizumab Cancer Management and Research Pembrolizumab Keytruda MK-3475 Melanoma Immune Checkpoint Inhibitor PD-1 Inhibitor Adjuvant Therapy Combination Therapies |
author_facet |
Abdul-Karim RM Cowey CL |
author_sort |
Abdul-Karim RM |
title |
Challenging the standard of care in advanced melanoma: focus on pembrolizumab |
title_short |
Challenging the standard of care in advanced melanoma: focus on pembrolizumab |
title_full |
Challenging the standard of care in advanced melanoma: focus on pembrolizumab |
title_fullStr |
Challenging the standard of care in advanced melanoma: focus on pembrolizumab |
title_full_unstemmed |
Challenging the standard of care in advanced melanoma: focus on pembrolizumab |
title_sort |
challenging the standard of care in advanced melanoma: focus on pembrolizumab |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2017-09-01 |
description |
Raghad M Abdul-Karim,1 C Lance Cowey2–4 1Baylor Sammons Cancer Center, 2Melanoma and Genitourinary Oncology Program, Baylor University Medical Center, Sammons Cancer Center Texas Oncology,3Baylor Skin Malignancy Research and Treatment Center, Baylor University Medical Center, 4Developmental Therapeutics Program, US Oncology Research, Dallas, TX, USA Abstract: The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability to improve both response rates and survival outcomes. Pembrolizumab, an immune checkpoint inhibitor that blocks the negative regulatory PD-1 receptor on T-cell lymphocytes, has shown improved efficacy compared to standard therapies with an acceptable tolerability profile. Additionally, this agent is being evaluated in adjuvant and combination trial strategies that have great potential to further advance outcomes. This review focuses on the advances that pembrolizumab has made in melanoma and what studies are upcoming that could change the future of melanoma treatment yet again. Keywords: keytruda, MK-3475, immune checkpoint inhibitor, PD-1 inhibitor, adjuvant therapy, combination therapies, immunotherapy |
topic |
Pembrolizumab Keytruda MK-3475 Melanoma Immune Checkpoint Inhibitor PD-1 Inhibitor Adjuvant Therapy Combination Therapies |
url |
https://www.dovepress.com/challenging-the-standard-of-care-in-advanced-melanoma-focus-on-pembrol-peer-reviewed-article-CMAR |
work_keys_str_mv |
AT abdulkarimrm challengingthestandardofcareinadvancedmelanomafocusonpembrolizumab AT coweycl challengingthestandardofcareinadvancedmelanomafocusonpembrolizumab |
_version_ |
1725496976628252672 |